Replies to post #241929 on Avid Bioservices Inc (CDMO)

[biopharm]

What is the difference between AZ'S PD-L1 and BMS OR MERCK.
How do they stack up since AZ and PPHM
enjoy a very amenable relationship.
AZ has more inventive since from a time line perspective they are behind the others.
How about efficacy???

I believe the PD-1's, PD-L1's, CTLA-4..etc..etc all will perform better with Bavituximab. The aging population and the young are the most affected with weak immune systems and for now...

I'm trying to chase down a few more leads with Gary Gilbert and his association with the VA Hospitals. I imagine some large clinical trials of some sort would be easy to implement within the patients at the VA hospital network and maybe David Shulkin knows more. Hell, the VA could easily work together with Peregrine and select some key indications to use a combination Bavituximab arm and I would think Gary Gilbert would agree.

Another question is if there is a stockpile of Bavituximab that could be planned.... can that stockpile also be privately used for the gov't to run trials without Peregrine ???

http://www.newengland.va.gov/research/clinicaltrialsnetwork/VA_USH_meets_with_Clinical_Trials_Network_Director.asp

---------------------------

Since Morristown Medical Center is a major affiliate to Rutgers... maybe David Shulkin and Gary Gilbert and Raymond Brige are all close as well. Hmmmm... : )

Carol G. Simon Cancer Center at Morristown Medical Center and Overlook Medical Center, part of Atlantic Health System, provides award-winning cancer care to patients in the New Jersey and New York metro area. We are a Major Clinical Affiliate of Rutgers Cancer Institute of New Jersey, the State’s only National Cancer Institute-designated Comprehensive Cancer Center. We have also received the Outstanding Achievement Award and Three Year Approval with Commendation from the American College of Surgeons Commission on Cancer.

http://www.cinj.org/network-hospitals/morristown-medical-center